Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that management will present at several upcoming investor events in December:
Evercore ISI 2nd Annual HealthCONx Conference. Company presentation on Tuesday, December 3, 2019 at 8:00 a.m. ET in Boston.
Piper Jaffray 31st Annual Healthcare Conference. Company presentation on Wednesday, December 4, 2019 at 8:00 a.m. ET in New York.
Evening CIDP KOL Symposium. Company will host a key opinion leader (KOL) evening symposium focused on the potential of efgartigimod to treat patients with chronic inflammatory demyelinating polyneuropathy (CIDP) on Thursday, December 5, 2019 at 4:30 p.m. ET in New York. The event will feature:
-
Data from Phase 1 healthy volunteer trial of ENHANZE® subcutaneous (SC) formulation of efgartigimod and development path forward to evaluate SC formulation in efgartigimod indications, including in CIDP.
-
Additional presentations from argenx management on potential efgartigimod market opportunity in CIDP, biological rationale of evaluating efgartigimod in CIDP, and design of upcoming Phase 2 trial on track to start by end of year.
-
Guest speaker Richard Lewis, M.D. from Cedars-Sinai Medical Center, who will highlight the CIDP treatment landscape.
Live webcasts of each event will be available on the Company’s website at www.argenx.com. Replays of the webcasts will be available for 90 days following each presentation on the argenx website.
About argenx
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe auto-immune diseases and cancer. The company is focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. argenx’s ability to execute on this focus is enabled by its suite of differentiated technologies. The SIMPLE AntibodyTM Platform, based on the powerful llama immune system, allows argenx to exploit novel and complex targets, and its three complementary Fc engineering technologies are designed to expand the therapeutic index of its product candidates.
For further information, please contact:
Beth DelGiacco, Vice President, Investor Relations
+1 518 424 4980
bdelgiacco@argenx.com
Joke Comijn, Director Corporate Communications & Investor Relations (EU)
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, forward-looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms believes, estimates, anticipates, expects, intends, may, will, or should and include statements argenx makes concerning the characteristics, market opportunity, development path and upcoming trial design of its product candidates and the intended results of its strategy.By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx’s actual results may differ materially from those predicted by the forward-looking statements as a result of various important factors, including argenx’s expectations regarding its the inherent uncertainties associated with competitive developments, preclinical and clinical trial and product development activities and regulatory approval requirements; argenx’s reliance on collaborations with third parties; estimating the commercial potential of argenx’s product candidates; argenx’s ability to obtain and maintain protection of intellectual property for its technologies and drugs; argenx’s limited operating history; and argenx’s ability to obtain additional funding for operations and to complete the development and commercialization of its product candidates. A further list and description of these risks, uncertainties and other risks can be found in argenx’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in argenx’s most recent annual report on Form 20-F filed with the SEC as well as subsequent filings and reports filed by argenx with the SEC. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. argenx undertakes no obligation to publicly update or revise the information in this press release, including any forward-looking statements, except as may be required by law.
